This product is for R&D purposes only and is not approved for human or veterinary use.
PT-141 (Bremelanotide research compound) is a laboratory-supplied compound intended for use in qualified research and institutional settings. This product is provided strictly for research purposes only and is commonly used in experimental studies investigating melanocortin receptor signaling, G protein-coupled pathway activation, and central nervous system receptor modeling under controlled conditions.
Research Context
PT-141 is a synthetic cyclic heptapeptide analog structurally related to alpha-melanocyte-stimulating hormone (α-MSH), and is widely studied in receptor pharmacology and neuropeptide research environments. It is frequently examined for its activity across the melanocortin receptor family, with particular research attention on MC3R and MC4R subtype interactions in experimental models. In research settings, PT-141 is commonly explored for its interaction with cyclic AMP signaling cascades, adenylate cyclase activation, and receptor-mediated intracellular response mechanisms. Investigators also study its receptor subtype selectivity profile, structural stability relative to linear melanocortin analogs, and comparative binding characteristics against related peptide compounds, making it a frequent reference compound in experimental models examining melanocortin pathway dynamics.
Research Overview
PT-141 is utilized in controlled laboratory workflows to support in vitro and in vivo investigations, including assays evaluating receptor binding affinity, downstream second messenger generation, and pathway activation kinetics. Researchers may employ this compound in biochemical assays, cell culture experiments, and experimental model systems to evaluate peptide stability, receptor selectivity, and dose-dependent signaling behavior under varying conditions.
Key Research Focus Areas
Melanocortin Receptor Studies: Investigating MC1R–MC5R subtype binding, agonist activity, and receptor selectivity profiles in controlled assay conditions.
G Protein-Coupled Signal Transduction: Studying adenylate cyclase activation, cyclic AMP accumulation, and downstream kinase cascade mechanisms.
Central Pathway Modeling: Exploring neuropeptide-receptor interactions and central nervous system signaling pathways in experimental models.
Peptide Structure-Activity Studies: Evaluating cyclic versus linear analog stability, sequence-dependent potency, and structural conformation effects in laboratory conditions.
Product Specifications
Compound Name
PT-141 (Bremelanotide)
Purity
≥ 99% (HPLC verified)
Molecular Classification
Synthetic cyclic heptapeptide (research compound)
Physical Form
Lyophilized (freeze-dried) powder
Net Content
10mg per sterile glass vial
Vial Material
Borosilicate laboratory-grade glass
Appearance
White to off-white solid
Storage Conditions
Store refrigerated at 2–8°C. Protect from light and moisture.
Intended Use
For laboratory research use only. Not for human or veterinary use.
Analytical verification documentation may be available upon request for qualified research institutions.
This research compound is provided in a controlled formulation intended to support stability, consistency, and reproducibility in laboratory workflows. Researchers should follow institutional safety standards, ethical protocols, and approved handling procedures when conducting experiments involving peptide compounds.
For research use only. Not for human or animal consumption.
This product has multiple variants. The options may be chosen on the product page
BATS Testing in progress
CERTIFICATE OF ANALYSIS COMING SOON
This product is currently undergoing third-party batch testing at our U.S.-based laboratory. The Certificate of Analysis will be published here once verification is complete.
COAs are typically available within a few business days of a new batch release.
